|
|
???tair.name??? >
???browser.page.title.author???
|
"kato k"???jsp.browse.items-by-author.description???
Showing items 1-10 of 42 (5 Page(s) Totally)
1 2 3 4 5 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2024-08-20 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku, N;Omori, T;Shitara, K;Sakuramoto, S;Yamaguchi, K;Kato, K;Kadowaki, S;Tsuji, K;Ryu, MH;Oh, DY;Oh, SC;Rha, SY;Lee, KW;Chung, IJ;Sym, SJ;Chen, LT;Chen, JS;Bai, LY;Nakada, T;Hagihara, S;Makino, R;Nishiyama, E;Kang, YK |
| 臺大學術典藏 |
2022-08-19T06:48:41Z |
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
|
Kitagawa Y.; Matsumura Y.; Takazawa A.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Ahn M.-J.; Kadowaki S.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Okada M.; Kato K. |
| 臺大學術典藏 |
2022-03-07T07:05:29Z |
Peak systolic velocity ratio derived from quantitative vessel analysis for restenosis after femoropopliteal intervention: a multidisciplinary review from Endovascular Asia
|
Kawarada O.; Hozawa K.; Zen K.; Huang H.-L.; Kim S.H.; Choi D.; Park K.; Kato K.; Kato T.; Tsubakimoto Y.; Ichihashi S.; Fujimura N.; Higashimori A.; Sato T.; Yan B.P.-Y.; Pang S.Y.-C.; Wongwanit C.; Leong Y.P.; Chua B.; George R.K.; Chen I.-C.; JEN-KUANG LEE; Hsu C.-H.; Pua U.; Iwata Y.; Miki K.; Okada K.; Obara H. |
| 國家衛生研究院 |
2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr
|
Kang, YK;Chen, LT;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Oh, SY;Choda, Y;Yasui, H;Takeuchi, K;Hirashima, Y;Hagihara, S;Boku, N |
| 臺大學術典藏 |
2022-01-05T03:36:40Z |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
|
Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2022-01-05T03:36:39Z |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. |
| 國家衛生研究院 |
2021-09-04 |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study
|
Kang, YK;Morita, S;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Chen, LT;Boku, N |
| 國家衛生研究院 |
2021-03-20 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Nishiyama, T;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2021-03-15 |
Dimethyl sulfoxide stimulates the AhR-Jdp2 axis to control ROS accumulation in mouse embryonic fibroblasts
|
Wuputra, K;Tsai, MH;Kato, K;Yang, YH;Pan, JB;Ku, CC;Noguchi, M;Kishikawa, S;Nakade, K;Chen, HL;Liu, CJ;Nakamura, Y;Kuo, KK;Lin, YC;Chan, TF;Wu, DC;Hou, MF;Huang, SK;Lin, CS;Yokoyama, KK |
| 臺大學術典藏 |
2021-02-19T06:52:26Z |
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
|
Kojima T.;Shah M.A.;Muro K.;Francois E.;Adenis A.;Chih-Hung Hsu;Doi T.;Moriwaki T.;Kim S.-B.;Lee S.-H.;Bennouna J.;Kato K.;Shen L.;Enzinger P.;Qin S.-K.;Ferreira P.;Chen J.;Girotto G.;De La Fouchardiere C.;Senellart H.;Al-Rajabi R.;Lordick F.;Wang R.;Suryawanshi S.;Bhagia P.;Peter Kang S.;Metges J.-P.;Keynote-181 Investigators; Kojima T.; Shah M.A.; Muro K.; Francois E.; Adenis A.; CHIH-HUNG HSU; Doi T.; Moriwaki T.; Kim S.-B.; Lee S.-H.; Bennouna J.; Kato K.; Shen L.; Enzinger P.; Qin S.-K.; Ferreira P.; Chen J.; Girotto G.; de la Fouchardiere C.; Senellart H.; Al-Rajabi R.; Lordick F.; Wang R.; Suryawanshi S.; Bhagia P.; Peter Kang S.; Metges J.-P.; KEYNOTE-181 Investigators |
Showing items 1-10 of 42 (5 Page(s) Totally)
1 2 3 4 5 > >>
View [10|25|50] records per page
|
